U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H50O
Molecular Weight 414.7067
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ?-sitosterol

SMILES

CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C

InChI

InChIKey=KZJWDPNRJALLNS-VJSFXXLFSA-N
InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-21,23-27,30H,7-9,11-18H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1

HIDE SMILES / InChI

Description

Beta-sitosterol is one of the main dietary phytosterols found in plants which have a similar skeleton as cholesterol. In human clinical trials, beta-sitosterol has been shown to have cholesterol-lowering effects and to relieve symptoms of benign prostatic hyperplasia. There has been a large amount of basic research conducted for potential applications of beta-sitosterol in a diverse range of conditions including cervical cancer, breast cancer, cystic fibrosis, and others. Beta-sitosterol is available over the counter as a natural health supplement and is marketed for a wide range of applications including headaches, tuberculosis, allergies, cancers, fibromyalgia, lupus, asthma, hair loss and many others.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Over 6 to 8 weeks beta-sitosterol supplementation of 12 g/day resulted in an average of 11% decrease in serum cholesterol and a 12% decrease in biliary cholesterol saturation.
Route of Administration: Oral
In Vitro Use Guide
Human cervical cancer cell lines, Caski and HeLa, were cultured in RPMI-1640 and supplemented with 10% foetal bovine serum and incubated at 37 deg-c in an atmosphere with 5% CO2. Cells were treated with 20 umol/L of beta-sitosterol for 48 hours and examined for changes by light microscopy, electron microscopy, and transmission electron microscopy. Changes in mRNA and protein expression were quantified using Real-Time qPCR and western blots. The treatment with beta-sitosterol reduced expression of PCNA, increased p53 mRNA, decreased the amount of HPV E6 transcripts. Cells treated with beta-sitosterol also exhibited loss of cell surface microvilli and increased electron density in the cell membrane.